Cell therapy weekly: T-cell therapy candidate receives IND clearance for high-risk COVID-19

Written by RegMedNet

Cell therapy weekly

This week: a T-cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients receives IND clearance from the US FDA, Hitachi Chemical’s cell and gene therapy business adopts a new name, Oxgene launches new technology for robust and reproducible AAV manufacture at scale, and AMSBIO announces a new optimized medium for expansion and maintenance of MSCs. The news highlights: T-cell therapy candidate receives IND clearance for the treatment of high-risk COVID-19 patients Minaris Regenerative Medicine: the new name for Hitachi Chemical’s cell and gene therapy business Oxgene launches new TESSA™ technology for robust and reproducible AAV manufacture at scale...

To view this content, please register now for access

It's completely free